Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CCN001
MIFTS: 51

Cocaine Dependence

Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Cocaine Dependence

About this section

MalaCards integrated aliases for Cocaine Dependence:

Name: Cocaine Dependence 12 76 55 15 73

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:9975
ICD10 33 F14.2
ICD9CM 35 304.2 304.20
MeSH 44 D019970
NCIt 50 C34492
SNOMED-CT 68 31956009
UMLS 73 C0600427
Sources

Summaries for Cocaine Dependence

About this section
Disease Ontology : 12 A drug dependence that is a psychological dependency on the regular use of cocaine.

MalaCards based summary : Cocaine Dependence is related to psychotic disorder and personality disorder. An important gene associated with Cocaine Dependence is DRD2 (Dopamine Receptor D2), and among its related pathways/superpathways are Circadian entrainment and Peptide ligand-binding receptors. The drugs Caffeine and Cocaine have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 76 Cocaine dependence is a psychological desire to use cocaine regularly. Cocaine overdose may result in... more...

Sources

Related Diseases for Cocaine Dependence

About this section

Diseases related to Cocaine Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 82)
# Related Disease Score Top Affiliating Genes
1 psychotic disorder 31.1 DRD2 DRD3 SLC6A3 SLC6A4
2 personality disorder 30.8 DRD2 SLC6A3 SLC6A4
3 antisocial personality disorder 30.5 DRD2 SLC6A3 SLC6A4
4 bipolar disorder 30.1 DBH DRD2 DRD3 SLC6A3 SLC6A4
5 schizophrenia 30.1 DBH DRD2 DRD3 SLC6A3 SLC6A4
6 pathological gambling 30.1 DRD2 DRD3 SLC6A3 SLC6A4
7 alexithymia 30.0 DRD2 SLC6A4
8 social phobia 29.9 DRD2 SLC6A4
9 cocaine abuse 29.8 DBH DRD2 SLC6A3 SLC6A4
10 attention deficit-hyperactivity disorder 29.8 DBH DRD2 DRD3 OPRM1 SLC6A3 SLC6A4
11 schizoaffective disorder 29.8 DRD2 DRD3 SLC6A4
12 alcohol abuse 29.8 DRD2 DRD3 SLC6A4
13 smoking as a quantitative trait locus 3 29.7 CHRNA3 CHRNA5
14 mood disorder 29.6 DRD2 DRD3 POMC SLC6A4
15 obsessive-compulsive disorder 29.5 DRD2 DRD3 PDYN SLC6A3 SLC6A4
16 substance abuse 29.5 DBH DRD2 DRD3 SLC6A3 SLC6A4
17 heroin dependence 29.4 DRD2 OPRD1 OPRM1 PDYN
18 major depressive disorder 29.4 DRD2 DRD3 POMC SLC6A3 SLC6A4
19 alcohol dependence 28.8 DBH DRD2 DRD3 OPRD1 OPRK1 OPRM1
20 tobacco addiction 28.7 CHRNA3 CHRNA5 CHRNB3 DRD2 OPRM1 SLC6A3
21 drug dependence 28.3 CHRNB3 DRD2 DRD3 OPRD1 OPRK1 OPRM1
22 cocaine intoxication 11.1
23 depression 10.3
24 tic disorder 10.3 DRD2 SLC6A3
25 polysubstance abuse 10.2 DRD2 DRD3
26 delusional disorder 10.2 DRD2 DRD3
27 tardive dyskinesia 10.2 DRD2 DRD3
28 impulse control disorder 10.2 DRD2 DRD3
29 striatonigral degeneration 10.2 DRD2 SLC6A3
30 periodic limb movement disorder 10.2 DRD2 SLC6A4
31 premature ejaculation 10.2 SLC6A3 SLC6A4
32 alcohol-induced mental disorder 10.1 DRD2 SLC6A3 SLC6A4
33 alcoholic psychosis 10.1 DRD2 SLC6A3 SLC6A4
34 cutaneous solitary mastocytoma 10.1 PDYN POMC
35 functioning pituitary adenoma 10.1 DRD2 POMC
36 movement disease 10.1 DRD2 DRD3 SLC6A3
37 migraine without aura 10.1 DRD2 DRD3 SLC6A4
38 phobic disorder 10.1 OPRK1 SLC6A4
39 stuttering 10.1 DBH DRD2 SLC6A3
40 multiple system atrophy 1 10.1 DBH DRD2 SLC6A3
41 gilles de la tourette syndrome 10.1 DBH DRD2 SLC6A3
42 narcolepsy 10.1 DRD2 PDYN SLC6A3
43 brunner syndrome 10.1 DBH SLC6A4
44 bruxism 10.1 DRD2 DRD3
45 opioid abuse 10.1 DRD2 OPRM1 PDYN
46 retrograde amnesia 10.1 PDYN POMC SLC6A4
47 agoraphobia 10.1 OPRK1 SLC6A4
48 separation anxiety disorder 10.1 OPRM1 SLC6A3
49 withdrawal disorder 10.0 OPRM1 PDYN POMC
50 oppositional defiant disorder 10.0 DBH DRD2 SLC6A3 SLC6A4

Graphical network of the top 20 diseases related to Cocaine Dependence:



Diseases related to Cocaine Dependence
Sources

Symptoms & Phenotypes for Cocaine Dependence

About this section

MGI Mouse Phenotypes related to Cocaine Dependence:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 CHRNA3 CHRNA5 CHRNB3 DBH DRD2 DRD3
2 homeostasis/metabolism MP:0005376 10 CHRNA3 DBH DRD2 DRD3 OPRD1 OPRK1
3 growth/size/body region MP:0005378 9.97 CHRNA3 DBH DRD2 DRD3 OPRM1 PDYN
4 adipose tissue MP:0005375 9.93 DBH DRD2 DRD3 OPRM1 PDYN POMC
5 endocrine/exocrine gland MP:0005379 9.91 DBH DRD2 OPRK1 OPRM1 POMC SLC6A3
6 digestive/alimentary MP:0005381 9.88 CHRNA3 DRD2 DRD3 OPRK1 OPRM1 PDYN
7 integument MP:0010771 9.81 DBH DRD2 OPRD1 OPRK1 OPRM1 PDYN
8 nervous system MP:0003631 9.73 CHRNA3 CHRNA5 DBH DRD2 DRD3 OPRD1
9 no phenotypic analysis MP:0003012 9.1 CHRNA3 DRD2 OPRD1 OPRM1 PDYN POMC
Sources

Drugs & Therapeutics for Cocaine Dependence

About this section

Drugs for Cocaine Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 328)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Caffeine Approved Phase 4,Phase 2,Phase 3,Phase 1 58-08-2 2519
2
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-36-2 5760 446220
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
4
Biperiden Approved, Investigational Phase 4,Phase 3,Phase 2 514-65-8 2381
5
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 64-17-5 702
6
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 616-91-1 12035
7
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 112111-43-0
8
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68693-11-8 4236
9
Risperidone Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 106266-06-2 5073
10
Azacitidine Approved, Investigational Phase 4 320-67-2 9444
11
Lamotrigine Approved, Investigational Phase 4,Phase 2 84057-84-1 3878
12
Carbamazepine Approved, Investigational Phase 4,Phase 2 298-46-4 2554
13
Methamphetamine Approved, Illicit Phase 4,Not Applicable 537-46-2 10836
14
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 300-62-9 5826 3007
15
Disulfiram Approved Phase 4,Phase 2,Phase 1 97-77-8 3117
16
Choline Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 62-49-7 305
17
Glutamic Acid Approved, Nutraceutical Phase 4,Phase 1,Early Phase 1 56-86-0 33032
18 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Parasympatholytics Phase 4,Phase 3,Phase 2,Phase 1
22 Antiparkinson Agents Phase 4,Phase 2,Phase 3,Phase 1
23 Purinergic P1 Receptor Antagonists Phase 4,Phase 2,Phase 3,Phase 1
24 Cholinergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
25 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Anesthetics, Local Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
30 Muscarinic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
31 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
32 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Biperiden lactate Phase 4,Phase 3,Phase 2
34 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
37 Antiviral Agents Phase 4,Phase 2,Phase 1,Early Phase 1
38 Antioxidants Phase 4,Phase 2,Phase 1,Early Phase 1
39 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Expectorants Phase 4,Phase 2,Phase 1,Early Phase 1
41 Respiratory System Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
42 Free Radical Scavengers Phase 4,Phase 2,Phase 1,Early Phase 1
43 N-monoacetylcystine Phase 4,Phase 2,Phase 1,Early Phase 1
44 Anti-Infective Agents, Local Phase 4,Phase 3,Phase 2
45 Antidotes Phase 4,Phase 2,Phase 1,Early Phase 1
46 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
47 Gastrointestinal Agents Phase 4,Phase 2,Phase 1,Not Applicable
48 Antipsychotic Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Tranquilizing Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 340)
# Name Status NCT ID Phase Drugs
1 Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence Unknown status NCT00495183 Phase 4 caffeine;Biperiden;Placebo
2 Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. Unknown status NCT03018236 Phase 4 Alcohol N-acetylcysteine;Alcohol Placebo;Cocaine N-acetylcysteine;Cocaine Placebo
3 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4 Citicoline;Placebo
4 An Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence Completed NCT00223210 Phase 4 Quetiapine;PLacebo
5 Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction Completed NCT02626494 Phase 4 N-Acetylcystein;Placebo
6 Lamotrigine add-on Therapy for Bipolar Disorder and Cocaine Dependency Completed NCT00280293 Phase 4 Lamotrigine;Placebo
7 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence - 9 Completed NCT00015275 Phase 4
8 Quetiapine for Cocaine Use and Cravings Completed NCT00232336 Phase 4 quetiapine
9 Pharmacotherapy and Intensive Treatment - 2 Completed NCT00000218 Phase 4 Carbamazepine
10 Effects of Modafinil in Methamphetamine Dependence Completed NCT00751023 Phase 4 Modafinil;Placebo
11 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Completed NCT00208143 Phase 4 Quetiapine;Risperidone
12 A PET Exploration of the Mechanism of Action of Dopamine Beta-hydroxylase Inhibition in Cocaine Addicts Withdrawn NCT02134002 Phase 4 Disulfiram;Placebo
13 Effectiveness of Topiramate in Treating Cocaine Dependent Individuals - 1 Unknown status NCT00249691 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
14 Novel Pharmacotherapy for Dual Dependence Unknown status NCT00448825 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
15 Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence Completed NCT01811940 Phase 2, Phase 3 Adderall-ER;Topiramate
16 Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence Completed NCT01468012 Phase 2, Phase 3 levodopa carbidopa and entacapone (LCE);Placebo
17 Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence Completed NCT00553319 Phase 2, Phase 3 Placebo;Adderall-XR;Adderall-XR
18 Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1 Completed NCT00032929 Phase 3 Selegiline
19 Brain Imaging Study of the Effects of Modafinil in Cocaine Addiction Completed NCT00701532 Phase 3 Modafinil and PET (brain imaging);placebo
20 Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence Completed NCT00167232 Phase 3 Naltrexone
21 Dose Response Trial of Pergolide for Cocaine Dependence - 1 Completed NCT00000248 Phase 3 Pergolide
22 Investigation of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients Completed NCT01134198 Phase 2, Phase 3 Mifepristone;placebo
23 Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1 Completed NCT00218660 Phase 3 Naltrexone;Placebo
24 Vigabatrin for the Treatment of Cocaine Dependency Completed NCT01281202 Phase 2, Phase 3 Vigabatrin;Matching Placebo
25 Adaptive Treatment for Alcohol and Cocaine Dependence Completed NCT01032135 Phase 2, Phase 3 medication management
26 Cocaine Use Reduction With Buprenorphine Completed NCT01402492 Phase 2, Phase 3 Buprenorphine + Naltrexone;Placebo + Naltrexone
27 Investigation of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients. Completed NCT02255357 Phase 2, Phase 3 Placebo;Intranasal Oxytocin
28 Cocaine/Crack and Reduction of Compulsion With Biperiden Completed NCT01251393 Phase 3 Biperiden;Placebo
29 Clinical Neurobiology of Serotonin and Addiction Completed NCT00732901 Phase 2, Phase 3 Escitalopram;Placebo
30 Progesterone Treatment for Cocaine-dependent Women: A Pilot Study Completed NCT00632099 Phase 2, Phase 3 Oral micronized progesterone;Placebo
31 Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients Completed NCT00495092 Phase 2, Phase 3 Caffeine;Biperiden;Placebo
32 Effect of Nefazodone on Relapse in Females With Cocaine Abuse - 10 Completed NCT00000293 Phase 3 Nefazodone
33 Smoking-Cessation and Stimulant Treatment (S-CAST) Completed NCT01077024 Phase 3
34 Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1 Completed NCT00061087 Phase 2, Phase 3 Methylphenidate;Bupropion
35 Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence Completed NCT00223236 Phase 3 Citicoline;Placebo
36 Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence Recruiting NCT02111798 Phase 2, Phase 3 Bupropion XL;placebo
37 Change the Cycle: An RCT to Prevent Injection Initiation Active, not recruiting NCT02774954 Phase 3
38 Randomised Placebo-Controlled Trial of Modafinil for Cocaine Dependence Unknown status NCT00123383 Phase 2 Modafinil
39 Study of the Effect of Magnetic Stimulation Repetitive Transcranial on Impulsivity in Cocaine Dependence Unknown status NCT01397266 Phase 2
40 A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence Unknown status NCT00737256 Phase 2 Aripiprazole;Perphenazine
41 Treating Cocaine Abuse: A Behavioral Approach Unknown status NCT01822327 Phase 2
42 Effects of Repeated Transcranial Magnetic Stimulation (rTMS) on the Treatment of Cocaine Addicted Patients Unknown status NCT01259362 Phase 2
43 Repetitive Transcranial Magnetic Stimulation in Symptoms of Attention Deficit Hyperactivity Disorder and Cognitive Function In Cocaine Addicts Unknown status NCT01593982 Phase 2
44 Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving Unknown status NCT01929343 Phase 2 lidocaine following cue-induced craving;lidocaine following neutral stimulus;saline
45 N-acetylcysteine (NAC) for Pediatric Obsessive-Compulsive Disorder Unknown status NCT01172275 Phase 2 N-Acetylcysteine;Placebo
46 Psychopharmacology for Cocaine Dependence - Buspirone Completed NCT01267292 Phase 2 Buspirone;Placebo for Buspirone;Methylphenidate;Placebo for Methylphenidate
47 Brain Function and Structure in Cocaine Dependence Completed NCT02080832 Phase 2 Citalopram;Placebo
48 Pharmacogenetics of Doxazosin for Cocaine Dependence Completed NCT01145183 Phase 2 Doxazosin;Placebo
49 Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence Completed NCT01486810 Phase 1, Phase 2 Lisdexamfetamine
50 Citalopram for Cocaine Dependence Completed NCT01535573 Phase 2 Citalopram;Citalopram;Placebo

Search NIH Clinical Center for Cocaine Dependence

Sources

Genetic Tests for Cocaine Dependence

About this section
Sources

Anatomical Context for Cocaine Dependence

About this section

MalaCards organs/tissues related to Cocaine Dependence:

41
Brain, Heart, Cortex, Testes, Prefrontal Cortex, Pituitary, Liver
Sources

Publications for Cocaine Dependence

About this section

Articles related to Cocaine Dependence:

(show top 50) (show all 628)
# Title Authors Year
1
fMRI Stroop and behavioral treatment for cocaine-dependence: Preliminary findings in methadone-maintained individuals. ( 30240978 )
2019
2
Neurostimulation techniques in the treatment of cocaine dependence: A review of the literature. ( 28822321 )
2018
3
How treatment improvement in ADHD and cocaine dependence are related to one another: A secondary analysis. ( 29775957 )
2018
4
Attentional bias toward alcohol stimuli as a predictor of treatment retention in cocaine dependence and alcohol user patients. ( 29136565 )
2018
5
Ventral striatal dysfunction in cocaine dependence - difference mapping for subregional resting state functional connectivity. ( 29915214 )
2018
6
Effect of continuing care for people with cocaine dependence on criminal justice sentences. ( 29460440 )
2018
7
Is Ayahuasca an Option for the Treatment of Crack Cocaine Dependence? ( 29608428 )
2018
8
Drug Stroop: Mechanisms of response to computerized cognitive behavioral therapy for cocaine dependence in a randomized clinical trial. ( 29258028 )
2018
9
Dynamic network dysfunction in cocaine dependence: Graph theoretical metrics and stop signal reaction time. ( 29876265 )
2018
10
Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence. ( 29422497 )
2018
11
Borderline Personality Disorder With Cocaine Dependence: Impulsivity, Emotional Dysregulation and Amygdala Functional Connectivity. ( 30108525 )
2018
12
Netrin G1: its downregulation in the nucleus accumbens of cocaine-conditioned mice and genetic association in human cocaine dependence. ( 28074533 )
2018
13
Comparing pharmacological treatments for cocaine dependence: Incorporation of methods for enhancing generalizability in meta-analytic studies. ( 29464791 )
2018
14
Pharmacogenetics of Dopamine β-Hydroxylase in cocaine dependence therapy with doxazosin. ( 29498170 )
2018
15
Symptoms of anhedonia, not depression, predict the outcome of treatment of cocaine dependence. ( 30032944 )
2018
16
Resting State Functional Connectivity of the Lateral and Medial Hypothalamus in Cocaine Dependence: An Exploratory Study. ( 30100886 )
2018
17
MiR-9, miR-153 and miR-124 are down-regulated by acute exposure to cocaine in a dopaminergic cell model and may contribute to cocaine dependence. ( 30166527 )
2018
18
Neuroimaging Metrics of Drug and Food Processing in Cocaine-Dependence, as a Function of Psychopathic Traits and Substance Use Severity. ( 30233344 )
2018
19
In Cocaine Dependence, Neural Prediction Errors During Loss Avoidance Are Increased With Cocaine Deprivation and Predict Drug Use. ( 30297162 )
2018
20
Modified cognitive behavioral therapy (M-CBT) for cocaine dependence: Development of treatment for cognitively impaired users and results from a Stage 1 trial. ( 30346186 )
2018
21
Galantamine and Computerized Cognitive Behavioral Therapy for Cocaine Dependence: A Randomized Clinical Trial. ( 29286595 )
2017
22
Reply to: kynurenic acid and alcohol and cocaine dependence: novel effects and multiple mechanisms? ( 27896378 )
2017
23
Functional neural changes following behavioral therapies and disulfiram for cocaine dependence. ( 28714728 )
2017
24
Cocaine dependence modulates the effect of HIV infection on brain activation during intertemporal decision making. ( 28711810 )
2017
25
Modafinil Treatment of Cocaine Dependence: A Systematic Review and Meta-Analysis. ( 28350194 )
2017
26
White Matter Changes in HIV+ Women with a History of Cocaine Dependence. ( 29163330 )
2017
27
Kynurenic acid and alcohol and cocaine dependence: novel effects and multiple mechanisms? ( 27885412 )
2017
28
Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence. ( 28857070 )
2017
29
A comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence. ( 28190084 )
2017
30
Sex differences in guanfacine effects on stress-induced stroop performance in cocaine dependence. ( 28823835 )
2017
31
A Novel Therapy for cocaine dependence during abstinence: A randomized clinical trial. ( 28894547 )
2017
32
Cocaine dependence does not contribute substantially to white matter abnormalities in HIV infection. ( 28251596 )
2017
33
Late Reduction of Cocaine Cravings in a Randomized, Double-Blind Trial of Aripiprazole vs Perphenazine in Schizophrenia and Comorbid Cocaine Dependence. ( 28984746 )
2017
34
Brain substrates of social decision-making in dual diagnosis: cocaine dependence and personality disorders. ( 26442666 )
2017
35
Dissociable Effects of Cocaine Dependence on Reward Processes: The Role of Acute Cocaine and Craving. ( 27545986 )
2017
36
Assessing the effects of cocaine dependence and pathological gambling using group-wise sparse representation of natural stimulus FMRI data. ( 27704410 )
2016
37
Efficacy of topiramate in the treatment of crack cocaine dependence: a double-blind, randomized, placebo-controlled trial. ( 27046312 )
2016
38
Cocaine dependence and thalamic functional connectivity: a multivariate pattern analysis. ( 27556009 )
2016
39
Effect of Continuing Care for Cocaine Dependence on HIV Sex-Risk Behaviors. ( 27224980 )
2016
40
A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. ( 26817621 )
2016
41
Neurofunctional Reward Processing Changes in Cocaine Dependence During Recovery. ( 26792441 )
2016
42
Modafinil and sleep architecture in an inpatient-outpatient treatment study of cocaine dependence. ( 26777774 )
2016
43
Psychostimulant drugs for cocaine dependence. ( 27670244 )
2016
44
A delta-opioid receptor genetic variant is associated with abstinence prior to and during cocaine dependence treatment. ( 27449273 )
2016
45
Just showing up is not enough: Homework adherence and outcome in cognitive-behavioral therapy for cocaine dependence. ( 27454780 )
2016
46
Attenuated neural response to emotional cues in cocaine-dependence: a preliminary analysis of gender differences. ( 27441590 )
2016
47
Mixed-amphetamine salts increase abstinence from marijuana in patients with co-occurring attention-deficit/hyperactivity disorder and cocaine dependence. ( 28051838 )
2016
48
Successful classification of cocaine dependence using brain imaging: a generalizable machine learning approach. ( 27766943 )
2016
49
A Highly Polymorphic Copy Number Variant in the NSF Gene is Associated with Cocaine Dependence. ( 27498889 )
2016
50
Topiramate for Cocaine Dependence: A Systematic Review and Meta-Analysis of Randomized Control Trials. ( 26826006 )
2016
Sources

Variations for Cocaine Dependence

About this section
Sources

Expression for Cocaine Dependence

About this section
Search GEO for disease gene expression data for Cocaine Dependence.
Sources

Pathways for Cocaine Dependence

About this section

Pathways related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Circadian entrainment 37
Show member pathways
 12.64 CHRNA3 DRD2 DRD3 OPRM1 SLC6A3
2
Peptide ligand-binding receptors 66
Show member pathways
 12.59 CHRNA3 CHRNA5 CHRNB3 DRD2 DRD3 OPRD1
3
Transmission across Chemical Synapses 66
Show member pathways
 12.57 CHRNA3 CHRNA5 CHRNB3 SLC6A3 SLC6A4
5
Amphetamine addiction 37
Show member pathways
 11.68 DRD2 PDYN SLC6A3
6
Interleukin-4 and 13 signaling 66
11.64 OPRD1 OPRM1 POMC
7
Postsynaptic nicotinic acetylcholine receptors 66
Show member pathways
 11.36 CHRNA3 CHRNA5 CHRNB3
8
Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics 61
Show member pathways
 11.27 CHRNA3 CHRNA5 DRD2 DRD3
9
Monoamine Transport 1
Show member pathways
 10.97 DBH SLC6A3 SLC6A4
10
Neurotransmitter Clearance In The Synaptic Cleft 66
Show member pathways
 10.89 SLC6A3 SLC6A4
11
DARPP-32 Phosphorylation 65
10.8 DRD2 DRD3
Sources

GO Terms for Cocaine Dependence

About this section

Cellular components related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.96 CHRNA3 CHRNA5 CHRNB3 DRD2 DRD3 OPRD1
2 synapse GO:0045202 9.88 CHRNA3 CHRNA5 CHRNB3 OPRK1
3 dendrite GO:0030425 9.88 CHRNA3 DRD2 OPRK1 OPRM1 PDYN
4 neuronal cell body GO:0043025 9.85 CHRNA3 OPRK1 PDYN SLC6A3
5 neuron projection GO:0043005 9.85 CHRNA3 CHRNA5 CHRNB3 SLC6A3 SLC6A4
6 postsynaptic membrane GO:0045211 9.83 CHRNA3 CHRNA5 CHRNB3 OPRD1
7 membrane raft GO:0045121 9.81 OPRD1 OPRM1 SLC6A3 SLC6A4
8 perikaryon GO:0043204 9.71 DRD2 OPRK1 OPRM1
9 axon terminus GO:0043679 9.62 DRD2 OPRD1 OPRK1 PDYN
10 integral component of synaptic vesicle membrane GO:0030285 9.58 OPRD1 OPRK1
11 dendrite membrane GO:0032590 9.57 OPRD1 OPRM1
12 integral component of postsynaptic membrane GO:0099055 9.55 DRD2 OPRK1 OPRM1 SLC6A3 SLC6A4
13 acetylcholine-gated channel complex GO:0005892 9.54 CHRNA3 CHRNA5 CHRNB3
14 spine apparatus GO:0097444 9.43 OPRD1 OPRM1
15 integral component of presynaptic membrane GO:0099056 9.43 DRD2 OPRD1 OPRK1 OPRM1 SLC6A3 SLC6A4
16 dopaminergic synapse GO:0098691 9.02 CHRNA5 CHRNB3 DRD2 DRD3 SLC6A3
17 membrane GO:0016020 10.3 CHRNA3 CHRNA5 CHRNB3 DBH DRD2 DRD3
18 integral component of membrane GO:0016021 10.24 CHRNA3 CHRNA5 CHRNB3 DBH DRD2 DRD3
19 plasma membrane GO:0005886 10.14 CHRNA3 CHRNA5 CHRNB3 DRD2 DRD3 OPRD1

Biological processes related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.98 DRD2 DRD3 SLC6A3 SLC6A4
2 chemical synaptic transmission GO:0007268 9.88 CHRNA3 CHRNA5 CHRNB3 DBH OPRK1 PDYN
3 regulation of membrane potential GO:0042391 9.87 CHRNA3 CHRNA5 CHRNB3
4 response to ethanol GO:0045471 9.83 DRD2 DRD3 OPRK1 OPRM1 SLC6A3
5 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.82 OPRD1 OPRK1 OPRM1
6 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.82 OPRD1 OPRK1 OPRM1
7 nervous system process GO:0050877 9.81 CHRNA3 CHRNA5 CHRNB3
8 regulation of synaptic vesicle exocytosis GO:2000300 9.8 CHRNA5 CHRNB3 DRD2
9 visual learning GO:0008542 9.79 DBH DRD2 DRD3
10 neuromuscular synaptic transmission GO:0007274 9.77 CHRNA3 CHRNA5 CHRNB3
11 response to amphetamine GO:0001975 9.76 DBH DRD2 DRD3
12 regulation of sensory perception of pain GO:0051930 9.75 OPRD1 OPRK1 OPRM1
13 positive regulation of cytokinesis GO:0032467 9.72 DRD2 DRD3
14 positive regulation of multicellular organism growth GO:0040018 9.72 DRD2 SLC6A3
15 response to radiation GO:0009314 9.72 OPRK1 OPRM1
16 associative learning GO:0008306 9.72 DBH DRD2
17 eating behavior GO:0042755 9.72 OPRD1 OPRK1 OPRM1
18 neuropeptide signaling pathway GO:0007218 9.72 OPRD1 OPRK1 OPRM1 PDYN POMC
19 negative regulation of blood pressure GO:0045776 9.71 DRD2 DRD3
20 positive regulation of neurogenesis GO:0050769 9.71 DRD2 OPRM1
21 arachidonic acid secretion GO:0050482 9.71 DRD2 DRD3
22 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.71 DRD2 DRD3
23 dopamine receptor signaling pathway GO:0007212 9.71 DRD2 DRD3
24 synaptic transmission, cholinergic GO:0007271 9.71 CHRNA3 CHRNA5 CHRNB3
25 negative regulation of protein secretion GO:0050709 9.7 DRD2 DRD3
26 response to iron ion GO:0010039 9.7 DRD2 SLC6A3
27 synaptic transmission, dopaminergic GO:0001963 9.7 DRD2 DRD3
28 estrous cycle GO:0044849 9.7 OPRK1 OPRM1
29 behavioral response to cocaine GO:0048148 9.7 DRD2 DRD3 OPRK1
30 dopamine metabolic process GO:0042417 9.69 DRD2 DRD3
31 neurotransmitter biosynthetic process GO:0042136 9.69 SLC6A3 SLC6A4
32 prepulse inhibition GO:0060134 9.69 DRD2 DRD3 SLC6A3
33 positive regulation of renal sodium excretion GO:0035815 9.68 DRD2 DRD3
34 maternal behavior GO:0042711 9.68 DBH OPRK1
35 G protein-coupled receptor internalization GO:0002031 9.68 DRD2 DRD3
36 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.67 DRD3 OPRM1
37 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.67 DRD2 DRD3
38 sensory perception GO:0007600 9.67 OPRK1 OPRM1
39 response to morphine GO:0043278 9.67 DRD2 DRD3 OPRK1 OPRM1
40 adenohypophysis development GO:0021984 9.66 DRD2 SLC6A3
41 monoamine transport GO:0015844 9.66 SLC6A3 SLC6A4
42 dopamine catabolic process GO:0042420 9.65 DBH SLC6A3
43 behavioral response to nicotine GO:0035095 9.65 CHRNA3 CHRNA5
44 behavioral response to ethanol GO:0048149 9.65 DBH DRD2 OPRM1
45 excitatory postsynaptic potential GO:0060079 9.65 CHRNA3 CHRNA5 CHRNB3 DRD2 OPRM1
46 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.64 DRD2 DRD3
47 opioid receptor signaling pathway GO:0038003 9.63 OPRD1 OPRK1 OPRM1
48 negative regulation of dopamine receptor signaling pathway GO:0060160 9.62 DRD2 DRD3
49 acid secretion GO:0046717 9.61 DRD2 DRD3
50 regulation of locomotion involved in locomotory behavior GO:0090325 9.61 DRD2 DRD3

Molecular functions related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.95 DRD2 DRD3 OPRD1 OPRK1 OPRM1
2 ion channel activity GO:0005216 9.74 CHRNA3 CHRNA5 CHRNB3
3 drug binding GO:0008144 9.69 DRD2 DRD3 SLC6A3
4 extracellular ligand-gated ion channel activity GO:0005230 9.61 CHRNA3 CHRNA5 CHRNB3
5 ligand-gated ion channel activity GO:0015276 9.58 CHRNA3 CHRNA5 CHRNB3
6 adrenergic receptor activity GO:0004935 9.56 DRD2 DRD3
7 neurotransmitter:sodium symporter activity GO:0005328 9.54 SLC6A3 SLC6A4
8 neuropeptide binding GO:0042923 9.54 OPRD1 OPRK1 OPRM1
9 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.52 DRD2 DRD3
10 acetylcholine binding GO:0042166 9.5 CHRNA3 CHRNA5 CHRNB3
11 monoamine transmembrane transporter activity GO:0008504 9.49 SLC6A3 SLC6A4
12 receptor serine/threonine kinase binding GO:0033612 9.48 OPRD1 OPRK1
13 dopamine neurotransmitter receptor activity GO:0004952 9.46 DRD2 DRD3
14 acetylcholine-gated cation-selective channel activity GO:0022848 9.43 CHRNA3 CHRNA5 CHRNB3
15 acetylcholine receptor activity GO:0015464 9.33 CHRNA3 CHRNA5 CHRNB3
16 dopamine binding GO:0035240 9.13 DRD2 DRD3 SLC6A3
17 opioid receptor activity GO:0004985 8.8 OPRD1 OPRK1 OPRM1
Sources

Sources for Cocaine Dependence

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....